SLC5A1 and pulmonary edema: Phlorizin, an inhibitor of SGLT1/2, reduced lung liquid and glucose absorption, increasing luminal glucose concentrations with potential adverse effects of pulmonary oedema and increased bacterial proliferation (Oliveira et al.,2016).